Galenica AG, previously Galenica Sante Ltd, is a Switzerland-based healthcare services and products provider. The Company's business i divided into three business sectors: Retail, Products & Brands, and Services. The Company manages a locally established pharmacies network in Switzerland. It develops and distributes its own product portfolio, as well as cooperates with a range of business partners, such as Pierre Fabre, Ales Groupe and Vitor Consumer Health for marketing and distribution of such brands as Perskindol, Triofan, A-Derma, Lierac, Phyto, Anti-Brumm and Algifor.
Galenica Sante's Services business sector is responsible for management of such logistics sector companies as Galexis, Unione Farmaceutica Distribuzione, Alloga and Medifilm..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 64.9K |
| Three Month Average Volume | 1.4M |
| High Low | |
| Fifty-Two Week High | 78.15 CHF |
| Fifty-Two Week Low | 65.1 CHF |
| Fifty-Two Week High Date | 26 Feb 2024 |
| Fifty-Two Week Low Date | 20 Oct 2023 |
| Price and Volume | |
| Current Price | 73.65 CHF |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -8.01% |
| Thirteen Week Relative Price Change | -4.86% |
| Twenty-Six Week Relative Price Change | -9.96% |
| Fifty-Two Week Relative Price Change | -6.14% |
| Year-to-Date Relative Price Change | -9.34% |
| Price Change | |
| One Day Price Change | 0.14% |
| Thirteen Week Price Change | -1.41% |
| Twenty-Six Week Price Change | -2.58% |
| Five Day Price Change | 1.87% |
| Fifty-Two Week Price Change | 4.91% |
| Year-to-Date Price Change | 1.24% |
| Month-to-Date Price Change | -3.66% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 29.52749 CHF |
| Book Value Per Share (Most Recent Quarter) | 28.21805 CHF |
| Tangible Book Value Per Share (Last Fiscal Year) | 7.88478 CHF |
| Tangible Book Value Per Share (Most Recent Quarter) | 6.01611 CHF |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 6.15958 CHF |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 75.07796 CHF |
| Revenue Per Share (Trailing Twelve Months) | 76.00853 CHF |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 2.2 CHF |
| Dividend Per Share (Trailing Twelve Months) | 2.2 CHF |
| Dividend Per Share (5 Year) | 2.02 CHF |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 3.30532 CHF |
| Excluding Extraordinary Items (Trailing Twelve Months) | 3.39863 CHF |
| Normalized (Last Fiscal Year) | 3.29393 CHF |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 3.30842 CHF |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 3.40204 CHF |
| Including Extraordinary Items (Last Fiscal Year) | 5.71936 CHF |
| Including Extraordinary Items (Trailing Twelve Months) | 3.55038 CHF |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.331 CHF |
| Cash Per Share (Most Recent Quarter) | 1.3956 CHF |
| Cash Flow Per Share (Last Fiscal Year) | 5.40197 CHF |
| Cash Flow Per Share (Trailing Twelve Months) | 5.50564 CHF |
| Free Cash Flow Per Share (Trailing Twelve Months) | 1.427 CHF |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | 3 |
| Cash Flow Revenue (Trailing Twelve Months) | 2 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 5.37% |
| Pretax Margin (Last Fiscal Year) | 5.20% |
| Pretax Margin (5 Year) | 5.35% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 27.81% |
| Gross Margin (Trailing Twelve Months) | 27.68% |
| Gross Margin (5 Year) | 26.37% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | 5.32% |
| Operating Margin (Trailing Twelve Months) | 5.51% |
| Operating Margin (5 Year) | 5.47% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 4.42% |
| Net Profit Margin (Trailing Twelve Months) | 4.49% |
| Net Profit Margin (5 Year) | 4.40% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 9.33% |
| Tangible Book Value (5 Year) | 19.45% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -2.82% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 2.64% |
| Revenue Growth (3 Year) | 3.43% |
| Revenue Change (Trailing Twelve Months) | 2.97% |
| Revenue Per Share Growth | 3.10% |
| Revenue Growth (5 Year) | 2.49% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 9.99% |
| Total Debt (5 Year) | 13.54% |
| Dividends | |
| Dividend Growth (3 Year) | 6.92% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 6.29% |
| EPS Change (Trailing Twelve Months) | 11.61% |
| EPS Growth (3 Year) | 1.93% |
| EPS Growth (5 Year) | -1.71% |
| EBITDA | |
| EBITDA (5 Year) | 15.00% |
| EBITDA (5 Year Interim) | 10.95% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -1.06% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 9 |
| Price to Tangible Book (Most Recent Quarter) | 12 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 94 |
| Price to Free Cash Per Share (Trailing Twelve Months) | 52 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 831.4M |
| Net Debt (Last Fiscal Year) | 658.7M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 |
| Price to Sales (Trailing Twelve Months) | 1 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 22 |
| PE Normalized (Last Fiscal Year) | 22 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 22 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 27 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 17 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 21 |
| Dividends | |
| Dividend Yield (5 Year) | 3.01% |
| Dividend Yield | 2.99% |
| Current Dividend Yield | 2.99% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 44 |
| Long Term Debt to Equity (Most Recent Quarter) | 52 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 66.21% |
| Payout Ratio (Trailing Twelve Months) | 64.36% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | 52 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 55 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 39.1M |
| Free Cash Flow (Trailing Twelve Months) | 71.2M |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | 27 |
| Net Interest Coverage (Trailing Twelve Months) | 369 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 53 |
| Total Debt to Equity (Most Recent Quarter) | 64 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 5.91% |
| Return on Assets (Trailing Twelve Months) | 5.86% |
| Return on Assets (5 Year) | 6.54% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 12.14% |
| Return on Equity (Trailing Twelve Months) | 12.42% |
| Return on Equity (5 Year) | 13.76% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 8.40% |
| Return on Investment (Trailing Twelve Months) | 7.96% |
| Return on Investment (5 Year) | 8.97% |